Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Acknowledgment to Referees

Acknowledgment to Referees Targ Oncol (2015) 10:449–451 DOI 10.1007/s11523-015-0401-x ACKNOWLEDGEMENT TO REFEREES Published online: 18 November 2015 Springer International Publishing Switzerland 2015 Dear Reader, As we approach the end of 2015, and publish our final issue of Targeted Oncology for the year, the editors and production staff at Adis wish to reflect on another successful year’s achievements and pay thanks to all those who have contributed their time and effort to guarantee the exceptional quality of our content. We are delighted to have seen the conclusion of formalities surrounding the joint venture of Springer Science+Business Media with Nature Publishing Group, Palgrave Macmillan, Macmillan Education in early May. Substantial ground has already been made in the integration of business within the resulting Springer Nature company and we at Adis look eagerly toward the future, as the benefits of the collective expertise and capabilities of this company carry us forward. The majority of our journals saw a rise in ISI impact factor against the previous year. Most notably, BioDrugs increased by 41% to 2.989; the European Journal of Drug Metabolism and Pharmacokinetics increased 19% to 1.563; CNS Drugs increased by 17% to 5.113; Targeted Oncology increased 16% to 4.000; Pediatric Drugs increased 15% to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

Acknowledgment to Referees

Targeted Oncology , Volume 10 (4) – Nov 18, 2015

Loading next page...
 
/lp/springer-journals/acknowledgment-to-referees-Ue0ZNb2XRh

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Oncology; Biomedicine general
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-015-0401-x
Publisher site
See Article on Publisher Site

Abstract

Targ Oncol (2015) 10:449–451 DOI 10.1007/s11523-015-0401-x ACKNOWLEDGEMENT TO REFEREES Published online: 18 November 2015 Springer International Publishing Switzerland 2015 Dear Reader, As we approach the end of 2015, and publish our final issue of Targeted Oncology for the year, the editors and production staff at Adis wish to reflect on another successful year’s achievements and pay thanks to all those who have contributed their time and effort to guarantee the exceptional quality of our content. We are delighted to have seen the conclusion of formalities surrounding the joint venture of Springer Science+Business Media with Nature Publishing Group, Palgrave Macmillan, Macmillan Education in early May. Substantial ground has already been made in the integration of business within the resulting Springer Nature company and we at Adis look eagerly toward the future, as the benefits of the collective expertise and capabilities of this company carry us forward. The majority of our journals saw a rise in ISI impact factor against the previous year. Most notably, BioDrugs increased by 41% to 2.989; the European Journal of Drug Metabolism and Pharmacokinetics increased 19% to 1.563; CNS Drugs increased by 17% to 5.113; Targeted Oncology increased 16% to 4.000; Pediatric Drugs increased 15% to

Journal

Targeted OncologySpringer Journals

Published: Nov 18, 2015

There are no references for this article.